Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων

New England Journal of Medicine. 2020 Dec 24; 383 (26) :
2526-2537.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in
First Remission.
Andrew H Wei, Hartmut Döhner, Christopher Pocock, Pau Montesinos,
Boris Afanasyev, Hervé Dombret, Farhad Ravandi, Hamid Sayar, Jun-Ho
Jang, Kimmo Porkka, Dominik Selleslag,...


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka


https://register.gotowebinar.com/register/6711366611927088656
Stem Cell Transplantation - a Post ASH 2020
Summary
Tuesday, February 2, 2021
Professor Arnon Nagler, MD, MSc
Participants: Prof.Spyridonidis, Dr Liga, Dr Tsokanas, Dr
Lekka


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka


Duration of shedding of viable SARS-CoV-2 in severely
immunosuppressed patients with
cancer
For most patients with COVID-19, persistently positive
nucleic acid
testing after symptom resolution does not indicate
prolonged
infectiousness. However, accumulating evidence suggests that
some
severely immunocompromised patients may have prolonged
shedding of
viable SARS-CoV-2. One study of 20 patients with...


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka


Study showing the different significance of allelia or Niall
epic tp53 mutation in AML as recently showed in MDS
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka


We discussed the use of Tki after allo hct for ph + ALL and
our current practice.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr
Kostopoulou
Leukemia. 2020 Nov 17;
A new pre-emptive TKIs
strategy for preventing relapse based on BCR/ABL monitoring for
Ph+ALL undergoing allo-HCT:...


In this large, prospective cohort of fit older adults
with advanced MDS, we found that survival was significantly
improved if HCT was performed early or for adverse risk disease but
not for standard risk disease with severe cytopenia.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas,...


A must read review.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Lekka, Dr Kostopoulou


Considerations on changing our current Camacho Based
protocol in a PTCY based protocol.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Lekka, Dr Kostopoulou


We presented the British guidelines for mrd monitoring.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Lekka, Dr Kostopoulou


Another study showing the superiority of adding in vivo
T cell depletion
Biol Blood Marrow
Transplant
. 2020 Oct;26(10):1868-1875.
doi:
10.1016/j.bbmt.2020.06.030.Epub
2020 Jul 5.
Unrelated Donor Transplant Recipients
Given Thymoglobuline Have Superior GRFS When Compared to Matched
Related Donor Recipients Undergoing Transplantation without
ATG
Jad Othman 1, Matthew Greenwood 2, John Moore 3, Stephen Larsen 4, Anne-Marie Watson 5, Chris Arthur 6, Abir
Bhattacharyya 7, Ian Bilmon 7, Emily Blyth 7, Adam...


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Lekka, Dr Kostopoulou


A retrospective study compared our
regimen of ptcy d3 and d5 with csa/MMf start at day 0/1 with other
combinations and in MV analysis showed better performance.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Lekka, Dr Kostopoulou
Timing of Post-Transplantation
Cyclophosphamide Administration in Haploidentical Transplantation:
A Comparative Study...


Μετά την έλευση 2 χρόνων από το προηγούμενο σεμινάριο, σας
προσκαλούμε με μεγάλη μας χαρά στο 2o
Εκπαιδευτικό Σεμινάριο στην Μεταμόσχευση Μυελού
των Οστών.
Την πρώτη μέρα του σεμιναρίου θα ανασκοπηθούν καινούρια
δεδομένα στην μεταμόσχευση μυελού και θα δοθεί
έμφαση στις επιπλοκές των καινούριων κυτταρικών
θεραπειών, τόσο επίκαιρες σήμερα, όπως το...


We discussed and we adapted the following protocol
BBMT 2018
Stem cell mobilization was achieved using granulocyte
colony-stimulating
factor (G-CSF) at 10 to16 μg/kg/day for 3 to 4 days after
dialysis on
dialysis days
Melphalan was dosed at 70 to 200 mg/m2 divided over2 days
(days -3 and
-2...


